Skip to main content

Walbert Timothy P's Form 4 filing

Horizon Therapeutics Public Ltd CoHZNP · filed Oct 1, 2021

Accession no.
0001209191-21-058424
Filed
Oct 1, 2021
Trade date
Sep 17-30, 2021
Filing delay
14 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 7 non-derivative transactions. Open-market sales total $5.52M. It was filed 14 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Walbert Timothy PCIK 0001349376Director, Officer (Chairman, President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 17, 2021Ordinary SharesGGiftDisposed−107,739$0.00$0739,984Direct
Sep 17, 2021Ordinary SharesGGiftAcquired+107,739$0.00$0107,739Indirect
Sep 17, 2021Ordinary SharesGGiftDisposed−110,502$0.00$0629,482Direct
Sep 17, 2021Ordinary SharesGGiftAcquired+110,502$0.00$0131,496Indirect
Sep 30, 2021Ordinary SharesSSaleDisposed−30,460$109.96F3−$3,349,381.6599,022Direct
Sep 30, 2021Ordinary SharesSSaleDisposed−18,940$110.80F4−$2,098,552580,082Direct
Sep 30, 2021Ordinary SharesSSaleDisposed−600$112.01F5−$67,206579,482Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.48 to $110.47 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.48 to $111.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)